Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States. It is involved in the development of core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. In addition, it engages in the development of product candidates for various disease indications, such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, non-alcoholic steatohepatitis, immuno-oncology, and clostridium difficile infections by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of selected microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ASMB
CUSIP92282210
Phone317-210-9311
Debt
Debt-to-Equity RatioN/A
Current Ratio9.30
Quick Ratio9.30
Price-To-Earnings
Trailing P/E Ratio-18.33
Forward P/E Ratio-12.48
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.02 million
Price / Sales100.65
Cash FlowN/A
Price / CashN/A
Book Value$5.62 per share
Price / Book7.86
Profitability
EPS (Most Recent Fiscal Year)($2.41)
Net Income$-42,800,000.00
Net Margins-379.22%
Return on Equity-56.56%
Return on Assets-32.21%
Miscellaneous
Employees79
Outstanding Shares20,550,000
Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions
What is Assembly Biosciences' stock symbol?
Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."
How were Assembly Biosciences' earnings last quarter?
Assembly Biosciences Inc (NASDAQ:ASMB) announced its quarterly earnings results on Monday, May, 7th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by $0.12. The biopharmaceutical company earned $3.57 million during the quarter, compared to analyst estimates of $1.88 million. Assembly Biosciences had a negative net margin of 379.22% and a negative return on equity of 56.56%. View Assembly Biosciences' Earnings History.
What price target have analysts set for ASMB?
3 brokers have issued 12-month target prices for Assembly Biosciences' stock. Their predictions range from $45.00 to $75.00. On average, they anticipate Assembly Biosciences' stock price to reach $56.6667 in the next twelve months. View Analyst Ratings for Assembly Biosciences.
Who are some of Assembly Biosciences' key competitors?
Some companies that are related to Assembly Biosciences include Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Supernus Pharmaceuticals (SUPN), Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), Portola Pharmaceuticals (PTLA), The Medicines (MDCO), Emergent Biosolutions (EBS), Evotec (EVTCY), TESARO (TSRO), OPKO Health (OPK), Intercept Pharmaceuticals (ICPT) and Clovis Oncology (CLVS).
Who are Assembly Biosciences' key executives?
Assembly Biosciences' management team includes the folowing people:
- Mr. Derek A. Small, Co-Founder, Pres, CEO & Director (Age 42)
- Dr. Uri A. Lopatin, Co-Founder, Chief Medical Officer and VP of R&D (Age 46)
- Dr. Richard J. Colonno, Exec. VP & Chief Scientific Officer of Virology Operations (Age 68)
- Mr. Thomas E. Rollins, Exec. Officer (Age 62)
- Mr. David J. Barrett CPA, Strategic Advisor Role (Age 42)
Has Assembly Biosciences been receiving favorable news coverage?
News articles about ASMB stock have been trending somewhat positive on Sunday, Accern Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Assembly Biosciences earned a news impact score of 0.03 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 45.27 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Assembly Biosciences' major shareholders?
Assembly Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include venBio Select Advisor LLC (5.32%), Rock Springs Capital Management LP (2.16%), Northern Trust Corp (1.09%), Lyon Street Capital LLC (0.68%), Victory Capital Management Inc. (0.60%) and JPMorgan Chase & Co. (0.53%). View Institutional Ownership Trends for Assembly Biosciences.
Which major investors are selling Assembly Biosciences stock?
ASMB stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BNP Paribas Arbitrage SA, JPMorgan Chase & Co., A.R.T. Advisors LLC, Hsbc Holdings PLC, Rock Springs Capital Management LP, California Public Employees Retirement System and EAM Global Investors LLC. View Insider Buying and Selling for Assembly Biosciences.
Which major investors are buying Assembly Biosciences stock?
ASMB stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Allianz Asset Management GmbH, Allianz Asset Management GmbH, venBio Select Advisor LLC, WINTON GROUP Ltd, Iguana Healthcare Management LLC, Lyon Street Capital LLC and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Assembly Biosciences.
How do I buy shares of Assembly Biosciences?
Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Assembly Biosciences' stock price today?
One share of ASMB stock can currently be purchased for approximately $44.18.
How big of a company is Assembly Biosciences?
Assembly Biosciences has a market capitalization of $939.37 million and generates $9.02 million in revenue each year. The biopharmaceutical company earns $-42,800,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Assembly Biosciences employs 79 workers across the globe.
How can I contact Assembly Biosciences?
Assembly Biosciences' mailing address is 11711 NORTH MERIDIAN STREET SUITE 310, CARMEL IN, 46032. The biopharmaceutical company can be reached via phone at 317-210-9311 or via email at [email protected]
MarketBeat Community Rating for Assembly Biosciences (ASMB)
MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe ASMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASMB will underperform the S&P 500 over the long term. You may vote once every thirty days.
